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Abstract
Attempts to target mutant KRAS have been unsuccessful. Here, we report the identification of Smad ubiquitination regula-
tory factor 2 (SMURF2) and UBCH5 as a critical E3:E2 complex maintaining KRAS protein stability. Loss of SMURF2 either
by small interfering RNA/short hairpin RNA (siRNA/shRNA) or by overexpression of a catalytically inactive mutant causes
KRAS degradation, whereas overexpression of wild-type SMURF2 enhances KRAS stability. Importantly, mutant KRAS
is more susceptible to SMURF2 loss where protein half-life decreases from >12 hours in control siRNA-treated cells to
<3 hours on Smurf2 silencing, whereas only marginal differences were noted for wild-type protein. This loss of mutant
KRAS could be rescued by overexpressing a siRNA-resistant wild-type SMURF2. Our data further show that SMURF2
monoubiquitinates UBCH5 at lysine 144 to form an active complex required for efficient degradation of a RAS-family E3,
β-transducing repeat containing protein 1 (β-TrCP1). Conversely, β-TrCP1 is accumulated on SMURF2 loss, leading to
increased KRAS degradation. Therefore, as expected, β-TrCP1 knockdown following Smurf2 siRNA treatment rescues
mutant KRAS loss. Further, we identify two conserved proline (P) residues in UBCH5 critical for SMURF2 interaction;
mutation of either of these P to alanine also destabilizes KRAS. As a proof of principle, we demonstrate that Smurf2 silencing
reduces the clonogenic survival in vitro and prolongs tumor latency in vivo in cancer cells including mutant KRAS-driven
tumors. Taken together, we show that SMURF2:UBCH5 complex is critical in maintaining KRAS protein stability and
propose that targeting such complex may be a unique strategy to degrade mutant KRAS to kill cancer cells.
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Introduction
KRAS is the most frequently mutated oncogenic driver, reported in
approximately 15% to 30% of all human malignancies, and is more
prevalent in pancreatic (90%), colon (50%), and lung (30%) cancers
[1–3]. Patients with tumors carrying a KRAS mutation show resis-
tance to anti–epidermal growth factor receptor (EGFR) therapies
[4–6], and attempts to target mutant KRAS have been unsuccessful
[7,8]. As KRAS activity is known to be regulated by farnesylation-
mediated protein modifications [9], farnesyl transferase inhibitors
have been developed. Although they were effective in preclinical
models, they failed in the clinic [10,11]. Therapeutic approaches to
inhibit KRAS downstream signaling have focused on the development
of kinase inhibitors targeting rapidly accelerated fibrosarcoma (RAF),
mitogen-activated protein kinase kinase (MEK), and extracellular
signal-regulated kinase (ERK). Only a minority of these provided
marginal survival advantage to patients carrying KRAS mutations,
and they also resulted in significant adverse events [12]. Recently,
various preclinical studies of synthetic lethality approaches targeting
specific kinases were also reported to specifically induce cell death
of mutant KRAS-driven tumors [13–17], but these approaches re-
main to be tested clinically. Hitherto, currently available therapeutic
approaches of indirectly targeting mutant KRAS have had limited
success [18–21] and there remains a great need to identify more
effective therapeutic approaches for KRAS mutant cancers.
On the basis of our recent findings as well as several independent
studies [22–25], we hypothesized that the physical loss or degrada-
tion of an oncoprotein provides a more robust and durable antitumor
effect compared to inhibition of oncogene function, a commonly
used strategy, which has so far provided only a transient antitumor
response. On the basis of such a provocative hypothesis, we felt the
need to better understand the regulators involved in maintaining
oncogene protein stability, particularly mutant KRAS. Increasingly,
it is becoming recognized that ubiquitin-mediated protein modifica-
tions of RAS family members (H-, N-, and KRAS) play critical roles
in protein abundance, maintenance of their activity, and association
with downstream signaling molecules. Particularly, in the case of
mutant KRAS, mono-/bi-ubiquitination enhances its GTP binding
and its association with downstream signaling molecules [26,27],
whereas polyubiquitination mediated through an F-box family E3,
β-transducing repeat containing protein 1 (β-TrCP1), induces RAS
degradation [28,29].
While investigating the role of Smad ubiquitination regulatory
factor 2 (SMURF2) in EGFR protein stability [22], we observed that
SMURF2 loss had greater impact on the clonogenic survival of
mutant KRAS-driven cancer cells compared to wild-type KRAS-
containing cell lines. In this report, we have extended this observa-
tion to several mutant KRAS-driven lung and colorectal cancer cell
lines and discovered that, although KRAS protein is stable (half-life >
12 hours) under normal physiological condition, on the loss of
SMURF2,mutant KRAS protein is rapidly degraded (half-life < 3 hours).
Subsequently, we found that targeting SMURF2 in mutant KRAS-
driven cells significantly reduces their clonogenic survival and growth
of tumor xenografts in nude mice. Furthermore, we have identi-
fied the molecular mechanism of SMURF2-mediated protection of
KRAS protein, where SMURF2 in complex with UBCH5 polyubiqui-
tinates and degrades RAS family E3, β-TrCP1, thus indirectly protects
KRAS from degradation. Furthermore, we found that in various
cancer cell lines as well as in a large cohort of human lung adeno-
carcinoma specimens Smurf2 and KRAS gene and protein expression
are significantly correlated, which suggests that these interactions occur
in patients.
Materials and Methods
Reagents
A monoclonal antibody against human SMURF2 has been de-
scribed previously [30]. Rabbit polyclonal SMURF2 antibody was
purchased from Upstate Biotechnology (Lake Placid, NY), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-TrCP1
antibodies were purchased from Cell Signaling Technology (Danvers,
MA). Anti-KRAS (F234, Cat. No. SC-30) and anti-ubiquitin (P4D1)
antibodies were acquired from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-KRAS (OP24) antibody was obtained from Calbiochem
(EMD Chemicals, San Diego, CA). Anti-MYC (Cat. No. 46-0603)
antibody was purchased from Invitrogen (Life Technologies, Grand
Island, NY). Anti-UBCH5 (UBE2D1, Cat. No. ab66600) antibody
was obtained from Abcam (Cambridge, MA). Anti-UBCH7 (Cat.
No. AB3859) antibody was obtained fromMillipore (EMDMillipore,
Billerica, MA). Sepharose-conjugated anti-FLAG (M2) antibody, pro-
tease inhibitor cocktail, and 3-methyladenine (3-MA; Cat.No.M9281)
were obtained from Sigma (St Louis, MO). Agarose-conjugated
anti–c-MYC monoclonal antibody (Cat. No. 631208) was ob-
tained from Clontech (Mountain View, CA). Glutathione-sepharose
beads were purchased from GE Healthcare (Pittsburgh, PA). Cyclo-
heximide (Cat. No. 239763) was obtained from Calbiochem
(EMD Chemicals). Control (Cat. No. D-001810), Smurf2 (Cat.
No. D-007194), β-TrCP (Cat. No. D-003463), and UbcH5 (Cat.
No. J-009387) small interfering RNA (siRNA) were purchased from
Thermo Fisher Scientific (Lafayette, CO), whereas another Smurf2
siRNA pool (Cat. No. sc-41675), Smurf1 (Cat. No. sc-41673), and
AIP4/ITCH (Cat. No. sc-40364) siRNAs were obtained from
Santa Cruz Biotechnology.
Cell Cultures
Human embryonic kidney–293 (HEK293) cell line, human lung
cancer cell lines (H2347, Hcc78, H358, H441, and A549), and cer-
vical carcinoma cell line (HeLa) were purchased from the American
Type Culture Collection (Manassas, VA) and were cultured either in
Dulbecco’s modified Eagle’s medium (for HEK293 and HeLa) or
RPMI-1640 (for rest of the cell lines) supplemented with 10%
FBS. Isogenic colorectal cancer cell lines (HCT116) harboring either
wild-type or mutant KRAS alleles were kind gifts from Dr Vogelstein
( Johns Hopkins University, Baltimore, MD) and were grown in
McCoy’s medium supplemented with 10% FBS. For plasmid trans-
fection, Lipofectamine 2000 (Invitrogen) and, for the siRNA transfec-
tion, Lipofectamine RNAi-max (Invitrogen) were used according to
the manufacturer’s instructions.
Protein Analyses
Immunoblot analysis and immunoprecipitation techniques were
performed as described previously [22] with a minor modification
of buffer, such that excess calcium was added [50 mM Hepes-
KOH (pH 7.5), 150 mM NaCl, 1.3 mM CaCl2, 1 mM DTT, 10 mM
β-glycerophosphate, 1 mM NaF, 0.1 mM sodium orthovanadate,
10% glycerol, 1% NP-40, and 1× protease inhibitor cocktail (Sigma;
Cat. No. P8340)].
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Glutathione S -Transferase Pull-Down Assay
Glutathione S -transferase (GST) pull-down assays were performed
as described previously [22]. Briefly, GST-SMURF2 proteins [either
wild-type or C716A (CA) mutants] were purified from bacteria by
standard techniques using GST-Sepharose beads (GE Healthcare)
and were equilibrated in 0.5× Superdex buffer [1× Superdex buffer:
25 mM Hepes (pH 7.5), 12.5 mMMgCl2, 10 μM ZnSO4, 150 mM
KCl, 20% glycerol, 0.1% NP-40, and 1 mM EDTA] by washing
three times with the buffer. The beads were then incubated with
about 500 ng of UBCH5 protein (Cat. No. E2-616; Boston Bio-
chemicals, Cambridge, MA) and incubated overnight at 4°C. The
beads were then washed three times using 0.5 Superdex buffer and
boiled in Laemmli buffer. The SMURF2:UBCH5 complex was
immunodetected using UBCH5- and SMURF2-specific antibodies.
Clonogenic Cell Survival Assay
Clonogenic survival assays were performed using techniques de-
scribed previously [31]. The effects of different siRNAs (e.g., Smurf2,
β-TrCP1, and UbcH5) on clonogenic survival of different cancer cell
lines were determined by normalizing the survival fraction of control
siRNA-treated group as 1.
RNA Isolation and Quantitation
Total cellular RNA was isolated using Qiagen RNeasy mini kit
(Qiagen, Inc, Valencia, CA) according to the manufacturer’s instruc-
tions. For quantitation, RNA samples (1 μg) were reverse transcribed
with random hexamers using the High-Capacity cDNA Reverse
Transcription System (Applied Biosystems, Foster City, CA). Real-
time polymerase chain reaction (PCR) was carried out with an ABI
Prism 7700 sequence detector using Power SYBR GREEN PCR
master mix (Applied Biosystems). The following human gene-
specific primers were used for the PCR reaction: 1) KRAS (forward,
5′ TACAGTGCAATGAGGGACCA 3′ and reverse, 5′ CTGT-
TCTAGAAGGCAAATCACA 3′) and 2) GAPDH (forward, 5′GAG-
TCAACGGATTTGGTCGT 3′ and reverse, 5′ TTGATTTTG-
GAGGGATCTCG 3′).
Lentiviral shRNA-Mediated Gene Knockdown
Control and Smurf2 small hairpin RNA (shRNA) lentiviral
constructs were obtained from Open Biosystems (Lafayette, CO),
and viral particles were produced using a standardized procedure
as described previously [32]. For efficient knockdown, target cells
were transduced twice with the lentiviral particles with an interval
of 24 hours, and 48 hours after the second transduction, cells were
lysed for immunoblot analysis to check Smurf2 knockdown efficiency
and also trypsinized and used for either clonogenic cell survival assays
or tumor xenograft studies.
Tumor Xenograft Studies
All animal procedures were carried out in accordance with a Uni-
versity Committee on Use and Care of Animals of the University of
Michigan–approved protocol. Briefly, either control or Smurf2
shRNA lentiviruses were transduced into H358 and HCT116 iso-
genic cell lines. To generate tumors, 300,000 cells were injected into
4- to 6-week-old female athymic nu/nu mice (Harlan Laboratories,
Indianapolis, IN). Tumor onset was detected by palpation by exam-
ining the mice on a regular basis, and tumor latency was calculated
on the basis of the time from injection to detection of palpable tumors.
Throughout the experiment, mice were weighed every other day, and
the length and width of the tumors were measured on a regular basis.
The tumor volumes were calculated using the formula 0.5 × length ×
width2 [33]. Relative tumor volumes were calculated by normalizing to
the tumor size when first detected.
In Vitro Ubiquitination Assay
The in vitro ubiquitination reaction was carried out in a 15-μl
reaction volume containing reaction buffer [250 mM Tris-HCl
(pH 7.5), 50 mM MgCl2, 50 μM DTT, and 20 mM ATP), 10 μg
of Myc-tagged ubiquitin (Cat. No. U-115), 0.35 μg of UBE1 (Cat.
No. E305), and 0.5 μg of UBCH5 (Cat. No. E2-616; all from Boston
Biochemicals), and Flag-tagged β-TrCP1 was overexpressed in
HEK293 cells and pulled down using affi-Flag (M2) beads. Human
recombinant SMURF2 protein (Cat. 468H; Creative Biomart,
New York, NY) was then added, and the reaction mixtures were incu-
bated at 37°C for 2 hours. The reaction was terminated after boiling
with 4× gel loading dye. The samples were then resolved and immuno-
blotted using indicated antibodies. For certain reactions where indi-
cated, GST-SMURF2 (either wild type or C716A mutants) proteins
were purified in the laboratory using a GST-Sepharose column and
were used in the in vitro ubiquitination assay.
Mass Spectrometry
The in vitro ubiquitination reaction mix was separated on a poly-
acrylamide gel, and proteins were visualized with colloidal Coomassie
stain. In-gel digestion followed by identification of ubiquitination site
mapping was carried out essentially as described previously [34]. Briefly,
on trypsin digestion, peptides were resolved on a nano-capillary reverse
phase column and subjected to a high-resolution, linear ion-trap mass
spectrometer (LTQ Orbitrap XL; Thermo Fisher Scientific). The full
mass spectrometry (MS) scan was collected in Orbitrap (resolution
30,000 at 400 m/z), and data-dependent MS/MS spectra on the nine
most intense ions from each full MS scan were acquired. Proteins
and peptides were identified by searching the data against Swissprot
human protein database, appended with decoy (reverse) sequences,
using X!Tandem/Trans-Proteomic Pipeline (TPP) software suite. All
proteins identified with a ProteinProphet probability of >0.9 (fdr <
1%) were accepted. Spectral matches to ubiquitinated peptides were
manually verified.
Analytical Size Exclusion Chromatography
Analytical size exclusion chromatography (SEC) was performed with
the purified GST-SMURF2 and UBCH5 using an S200pc.column
and AKTAmicro (GE Healthcare) equilibrated with buffer [50 mM
Hepes (pH 8.0) and 100 mM NaCl] at 4°C. In a 50-μl reaction vol-
ume, 50 μg each of affinity-purified GST-SMURF2 and UBCH5 were
mixed either in the presence or absence of in vitro ubiquitination
components (as mentioned above). Reactions were then incubated at
37°C for 2 hours. Each reaction mixture was then injected into the
pre-equilibrated SEC column. Fractions (50 μl per fraction) were
collected in a 96-well plate and A280 values were measured to identify
protein fractions. A tenth of such protein fractions were then subjected
to immunoblot analysis using SMURF2 and UBCH5 antibodies.
Statistics
Pearson correlation (r) was used to quantify the correlation between
SMURF2 and KRAS. Unless noted otherwise, results are presented
as mean ± standard error of the mean (SEM; estimate) of at least three
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experiments. To assess the correlation between KRAS and SMURF2,
we first normalized their values by calculating the ratios KRAS/
GAPDH and SMURF2/GAPDH. We then calculated Pearson corre-
lation coefficients for the log of the normalized KRAS and SMURF2
values. Time to tumor detection was calculated as the time from in-
jection of cells to detection of palpable tumors. The Kaplan-Meier
method was used to summarize time to development of tumor in mice
under various experimental conditions, and the log-rank test was used
to compare groups with respect to time to tumor development. Mice
without a tumor at the end of the study were censored at that time. A
significance level threshold of two-sided P < .05 was used to determine
statistical significance.
Results
SMURF2 Ligase Activity Maintains KRAS Steady-State Levels
To explore the involvement of SMURF2 on KRAS steady-state
levels, we altered SMURF2 levels and catalytic activity either by
using multiple siRNA/shRNA or by overexpressing wild-type and
catalytically inactive mutant (Cys716Ala) of SMURF2, respectively.
As shown in Figure 1A and quantified in Figure 1B, knockdown of
Smurf2 in mutant KRAS-driven lung adenocarcinoma cell lines
[H358 (KRASG12C) and H441 (KRASG12V)] caused ∼60% to
80% reduction in mutant KRAS steady-state levels compared to con-
trol siRNA-treated cells as early as 24 hours post-transfection
(Figure 1A, compare lanes 1 and 2; lanes 3 and 4). In lung adeno-
carcinoma cell lines carrying wild-type KRAS (H2347), silencing of
Smurf2 had minimal effects on wild-type KRAS protein steady-state
level (Figure 1A, lanes 5 and 6). Using different siRNAs (S1 and S2)
for Smurf2 and different cell lines (HeLa and A549), we found that loss
of endogenous Smurf2 leads to reduced steady-state levels of KRAS
(Figure W1A). Probing the membrane with different KRAS antibodies
confirmed our observation (Figure W1A). To show the Smurf2 knock-
down specificity on KRAS steady-state levels, we performed rescue
experiments by overexpressing an siRNA-resistant (si-R) construct of
wild-type SMURF2. Expression of SMURF2 si-R before siRNA trans-
fection significantly rescued the KRAS down-regulation (Figure 1C ).
Furthermore, our study with several other homologous to E6AP
carboxyl terminus (HECT)-type ubiquitin ligases (SMURF1 and AIP4/
ITCH) showed no alteration in KRAS steady-state level (Figure W1B),
suggesting SMURF2 specificity.
To test the importance of SMURF2 ubiquitin ligase activity in
regulating KRAS steady-state levels, we co-overexpressed FLAG-
tagged wild type or a ligase-dead Cys716Ala (CA) mutant of SMURF2
with Myc-tagged KRAS [either wild-type or different mutants (G12D/
V/C/S)] in HEK293 cells. Overexpression of wild-type SMURF2
increased mutant (G12D, V, C or S) KRAS steady-state levels,
whereas SMURF2 (CA) overexpression downregulated KRAS sig-
nificantly (Figure 1D), indicating the importance of SMURF2
Figure 1. SMURF2 ubiquitin ligase activity controls mutant KRAS steady-state levels. (A) H358 (KRASG12C), H441 (KRASG12V), and H2347
(KRASWT) human lung adenocarcinoma cells were transfected with either control (C) or Smurf2 (S) siRNA. Forty-eight hours post-
transfection, cell lysates were subjected to immunoblot analysis using specified antibodies. (B) Quantification of KRAS steady-state level
in H358, H441, and H2347 cells on C or S siRNA. Immunoblot obtained from A were scanned and quantified using ImageJ software, and
KRAS steady-state levels were normalized using GAPDH as loading control. Relative KRAS protein levels were obtained, and mean ± SEM
values were calculated from three independent experiments; * denotes significant difference from control at P < .05; **, denotes sig-
nificant difference from control at P < .005; NS, not significant. (C) H441 cells were transfected with Smurf2 si-R (SM2-siR) construct
before siRNA-mediated Smurf2 knockdown. Cell lysates were prepared 24 hours post siRNA transfection and immunoblotted using
indicated antibodies. (D) HEK293 cells were co-transfected with Myc-tagged KRAS [either wild type or various mutants (G12D, V, C, or S)]
in the presence or absence of FLAG-tagged SMURF2 [either wild type or C716A (CA) mutants]. Twelve hours post-transfection, cell lysates
were prepared and subjected to immunoblot analysis using indicated antibodies.
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ubiquitin ligase activity in maintaining KRAS levels. As shown
earlier, we also noted that SMURF2 (CA) expression was signifi-
cantly higher than SMURF2 (wild type), because SMURF2 (CA)
is unable to undergo auto-ubiquitination–mediated degradation [35].
Taken together, these results show the critical involvement of
SMURF2 physical presence and ubiquitin ligase activity in maintaining
steady-state levels of KRAS and most importantly mutant form of
the protein.
SMURF2 Ubiquitin Ligase Activity Positively Regulates
KRAS Protein Stability
To address whether the changes in KRAS steady-state levels result-
ing from SMURF2 depletion or overexpression are due to changes in
KRAS protein stability or changes in gene transcription, we per-
formed experiments using lysosomal or proteasomal inhibitors and
protein half-life studies using the protein synthesis inhibitor cyclo-
heximide and also quantitated KRAS gene transcription following
SMURF2 alterations. As shown in Figure 2A, a lysosomal inhibitor,
3-MA, not only increased the steady-state basal level of KRAS (lane 5),
indicative of constitutive lysosomal degradation of KRAS in cells,
but it also protected against SMURF2 (CA)–mediated KRAS
down-regulation (compare lanes 3 and 6). In this study, the pro-
teasomal inhibitor MG132 had minimal protective effects on
SMURF2 (CA)–mediated KRAS down-regulation (Figure 2A, lane
9), supporting the notion that KRAS degradation might occur in the
lysosomes [36]. (This is in contrast to other RAS family members
such as H- or N-RAS, which undergo proteasomal degradation.)
[28,29] Furthermore, in HEK293 cells overexpressing KRAS-G12V,
the protein half-life decreased from >12 hours to ∼3.5 hours following
SMURF2 (CA) overexpression [Figure 2, B (right panel) and C], sug-
gesting the importance of SMURF2 ligase activity on mutant KRAS
protein stability. To determine the half-life of the endogenous KRAS
protein on Smurf2 knockdown, we transfected lung cancer cells
carrying either wild type (H2347) or KRAS-G12V (H441) with either
control or Smurf2 siRNA. As shown in Figure 2D and quantified in
Figure 2E , on Smurf2 loss, mutant KRAS half-life was reduced
from >12 hours to ∼2.5 hours, whereas wild-type KRAS half-life
changed marginally, indicating that KRAS-G12V protein was more
Figure 2. Ubiquitin ligase activity of SMURF2 positively regulates KRAS protein stability. (A) HEK293 cells were transfected with KRAS in
the presence or absence of SMURF2 (SM2) CA. Twelve hours post-transfection, indicated cells were treated with either 5 mM 3-MA or
2 μMMG132 for 4 hours. Cell lysates were then subjected to immunoblot analysis with the indicated antibodies. (B) HEK293 cells were
transfected either with G12V mutant KRAS in the presence or absence of SM2-CA. Twelve hours post-transfection, cells were treated
with cycloheximide (50 μg/ml), and cell lysates were harvested at the indicated time points and analyzed by immunoblot analysis with
the antibodies mentioned. (C) Graphical representation of the quantification of KRAS protein levels shown in B to determine protein half-
life. Relative KRAS levels were determined by densitometric scanning of the representative immunoblot considering 0 hour band inten-
sity as 1 (arbitrary units). (D) Endogenous KRAS half-life was determined for H2347 and H441 cells on Smurf2 knockdown. Indicated
cells were transfected with Smurf2 siRNA, and 48 hours post-transfection, cells were treated with cycloheximide (50 μg/ml), harvested
at indicated times, and analyzed by immunoblot analysis. (E) Protein half-lives were determined as explained in C. Each value represents
protein intensity average ± SD from three independent experiments and plotted on a log-linear scale.
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labile on Smurf2 loss. In a similar experiment, KRAS-G12C mutant
behaved similarly as KRAS-G12V protein. In contrast, KRAS gene
transcription remained unaffected on Smurf2 knockdown (Figure W2).
Taken together, these data support the involvement of SMURF2 ubi-
quitin ligase activity in maintaining KRAS protein stability including
the mutant form.
SMURF2 Downregulates β-TrCP1 to Indirectly Protect
Mutant KRAS from Degradation
Recently, β-TrCP, an F-box ubiquitin ligase, has been implicated
in RAS (including KRAS) ubiquitination and degradation [28,29].
As reported earlier, we also observed that siRNA-mediated down-
regulation of β-TrCP1 in mutant KRAS-driven H358 and H441
cells enhances KRAS steady-state level (Figure W3A); overexpression
of β-TrCP1 causes degradation of KRAS (Figure W3B), and immuno-
precipitation studies show interaction between KRAS and β-TrCP1
only when KRAS degradation was inhibited by a lysosomal inhibitor,
3-MA (Figure W3C ). To determine the role of β-TrCP1 in degra-
dation of KRAS on Smurf2 siRNA-mediated down-regulation, we
knocked down β-TrCP1 by siRNA before altering SMURF2 expres-
sion. As shown in Figure 3A, prior down-regulation of β-TrCP1 pro-
tected Smurf2 siRNA-mediated KRAS down-regulation, pointing to its
involvement in the process. Prior knockdown of other ubiquitin ligases
including a β-TrCP1 homologue, β-TrCP2, did not rescue Smurf2
siRNA-mediated KRAS down-regulation (data not shown). Taken
together, our data show that on loss of SMURF2, β-TrCP1 degrades
mutant KRAS effectively. We also observed that with Smurf2 siRNA
treatment, the steady-state level of β-TrCP1 was significantly higher
(Figure 3, A and B). Furthermore, protein half-life studies indicated
enhanced β-TrCP1 stabilization; t1/2 ∼ 1.5 hours for control siRNA-
treated cells compared to ∼5 hours in Smurf2 siRNA-treated cells
(Figure 3, C andD), thus supporting the role of SMURF2 in β-TrCP1
degradation. Similarly, overexpression of wild-type SMURF2 reduced
β-TrCP1 levels, whereas overexpression of the SMURF2 (CA) mutant
caused up-regulation of β-TrCP1 similar to Smurf2 siRNA treatment
(Figure 3E). Using in vivo ubiquitination studies, we demonstrated that
inH441 cells, overexpression of wild-type SMURF2 enhances β-TrCP1
polyubiquitination, whereas overexpression of catalytically inactive
SMURF2 (CA) mutant inhibits it (Figure 3F ). Furthermore, as
SMURF2 is known to partner with different E2s including UBCH7
and UBCH5 [35,37], we examined the involvement of SMURF2
ubiquitination machinery components in β-TrCP1 polyubiquitination
using in vitro ubiquitination assay. Results obtained from this study
demonstrate enhanced polyubiquitination of β-TrCP1 in the presence
of purified SMURF2 and UBCH5 (Figure 3G ). Taken together, our
data suggest that SMURF2:UBCH5 is the E3:E2 complex responsible
for down-regulation of β-TrCP1, and in the absence of SMURF2,
β-TrCP1 is stabilized, leading to an efficient degradation of KRAS.
Smurf2 Knockdown Reduces Clonogenic Survival and
Increases Tumor Latency Including the Mutant
KRAS-Driven Cancer Cells
To address the functional importance of SMURF2-mediated
KRAS stabilization, we performed clonogenic survival assays on
Smurf2 alteration using various lung adenocarcinoma cells carrying
either wild-type or mutant KRAS alleles. Smurf2 loss reduced the
clonogenic survival of mutant KRAS-driven H358 (KRASG12C)
and H441 (KRASG12V) cells to 0.03 ± 0.002 and 0.05 ± 0.01,
respectively, compared to 0.21 ± 0.03 in the case of wild-type KRAS
containing H2347 cells (Figure 4A). Similarly, Smurf2 knockdown
in HCT116 isogenic lines reduced the clonogenic survival to 0.25 ±
0.1 in wild-type KRAS HCT116 cells and to 0.08 ± 0.02 in mutant
KRASG13D-HCT116 isogenic cells compared to control siRNA-
treated cells (Figure 4B). In our previous studies, we have shown
Smurf2 knockdown had minimal effects on clonogenic survival of
various noncancerous cells (e.g., Het-1A and NIH-3T3 and CHO
cells) [22]. As the effect of siRNA-mediated gene silencing is transient,
we also used lentiviral vectors encoding Smurf2 shRNA (Table W1).
As shown in Figure 4C , infection of cells with two different Smurf2
shRNA (shRNA#3 and 4) reduced SMURF2 expression and caused
KRAS down-regulation (Figure W4, A and B). Like Smurf2 siRNA-
treated cells, lentivirus-infected Smurf2 shRNA-expressing cells
showed a significant decrease (0.41 ± 0.04 for H358 and 0.61 ± 0.05
for H441 cells) in clonogenic survival (Figure 4C ), supporting the
critical function of SMURF2 in regulating the clonogenic survival of
cancer cells including mutant KRAS-driven cells. shRNA-mediated
Smurf2 knockdown had a lesser effect on clonogenic survival (0.79 ±
0.2) of wild-type KRAS-driven H2347 cells.
To test the in vivo relevance of such observations, we assessed the
tumor forming potential of mutant KRAS (G12C) H358 and colo-
rectal isogenic HCT116 cells carrying either wild-type or mutant
KRAS, on transduction with control or Smurf2 shRNA. As shown
in Figure 4D and tabulated in Figure 4F , control shRNA-treated
H358 cells formed palpable tumors with a mean time of tumor detec-
tion of 10.5 days, which Smurf2 knockdown prolonged to 42.5 days
(P < .005). For HCT116 isogenic cells, the mean time until tumor
detection was calculated to be 7 days for both wild-type and mutant
KRAS cells. Interestingly, Smurf2 down-regulation increased median
time to tumor detection to 14 days post-injection for wild-type (P <
.0003) and to 24 days for mutant (P < .004) KRAS, respectively (Fig-
ure 4, E and F). Such studies demonstrate the critical importance of
SMURF2 in maintaining the tumorigenic potential of cancer cells
including mutated KRAS-driven cells.
SMURF2 and KRAS Protein and Gene Expression Are Highly
Correlated in Patients with Lung Adenocarcinoma
To address the physiological and clinical relevance of our observa-
tion, we started by assessing the relationship between protein expres-
sion of KRAS and SMURF2 using cell lysates isolated from a variety
of cancer and normal cell lines. As shown in Figure 5A, SMURF2
and KRAS protein expression were positively correlated (r = 0.39,
n = 25, P = .05), suggesting the physiological relevance of our obser-
vation. Although it would be desirable to attempt to correlate KRAS
and SMURF2 protein expression in patient samples, this is not pos-
sible because of the lack of availability of immunohistochemistry
compatible KRAS-specific antibodies. To explore the clinical importance
of our findings, we analyzed the gene expression data from 595 patients
with lung adenocarcinoma and 130 patients with squamous lung
cancer measured using oligonucleotide arrays. We found a highly sig-
nificant correlation (r = 0.49, n = 595, P < .0001) between Smurf2 and
KRAS gene expression among patients with lung adenocarcinoma
[38,39] (Figure 5B). Among squamous lung cancers, the correlation
was lower but still significant (r = 0.24, n = 130, and P < .005) [40]
(Figure 5B). This was further supported by data available in the public
domain, where a strong correlation between Smurf2 and KRAS gene
expression was observed in 79 lung cancer cell lines (r = 0.31, n =
79, P = .005) [41] and among patients with nonhistologically defined
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Figure 3. SMURF2 destabilizes β-TrCP1 to indirectly protect mutant KRAS from degradation. (A) H441 cells were transfected with either
control or β-TrCP1 (βT1) siRNA before Smurf2 (S) knockdown. Twenty-four hours post-transfection, cell lysates were subjected to
immunoblot analysis. (B) H358 and H441 cells were transfected with either C or S siRNA, and cell lysates were subjected to immunoblot
analysis. (C) H441 cells were transfected with either control (C) or Smurf2 (S) siRNA. Twenty-four hours post-transfection, cells were
treated with 50 μg/ml cycloheximide (CHX) for the indicated times. Cell lysates were prepared and subjected to immunoblot analysis. (D)
Protein half-life of β-TrCP1 was determined as explained above. (E) HEK293 cells were transfected with either wild type or catalytically
inactive (CA) mutants of SMURF2 along with β-TrCP1 as indicated. Twenty-four hours post-transfection, cell lysates were prepared and
subjected to immunoblot analysis. (F) H441 cells were transfected with β-TrCP1 either alone or in combination with SMURF2 (either wild
type or CA mutants). Forty-eight hours post-transfection, cells were treated with MG132, and 4 hours post-treatment, cell lysates were
subjected to immunoprecipitation with β-TrCP1 antibodies followed by immunoblot analysis using indicated antibodies. (G) In vitro ubi-
quitination assays were performed using immunoprecipitated Flag-tagged β-TrCP1 in the presence or absence of purified recombinant
SMURF2. UBCH5, a known E2 for SMURF2, was used in the reaction. Immunoblot analyses were performed using indicated antibodies.
Neoplasia Vol. 16, No. 2, 2014 SMURF2:UBCH5 Maintains KRAS Protein Stability Shukla et al. 121
non-small cell lung cancer (NSCLC; r = 0.46, n = 183, P < .001)
[42,43] (Figure 5B). We determined the KRAS gene mutation status
for 54 patients with lung adenocarcinoma in 100 tumors analyzed in
the Director’s Challenge Consortium for the Molecular Classification
of Lung Adenocarcinoma [38]. In this cohort, 28 patients had KRAS
mutations particularly at G12 and G13 amino acids, and interestingly,
their Smurf2 gene expression was higher compared to the patients
carrying wild-type KRAS (Figure W5). Interestingly, β-TrCP1 gene
expression was found to be inversely correlated to both Smurf2
(−0.41, n = 595, P < .00001; Figure W6A) and KRAS (−0.52, n =
595, P < .0001; Figure W6B) gene expression in patients with lung
adenocarcinoma, suggesting the clinical relevance of our findings.
However, the mechanisms underlying these clinical correlations at
the transcript levels are as yet undetermined.
SMURF2 Monoubiquitinates UBCH5 at the K144 Position
to Form a Stable Complex, Which Is Essential for
Maintaining KRAS Stability
While performing SMURF2:UBCH5-mediated in vitro ubiquiti-
nation unexpectedly, we further identified monoubiquitinated species
Figure 4. Smurf2 knockdown reduces clonogenic survival and increases tumor latency in KRAS-mutated cancer cells. (A) H358, H441,
and H2347 cells were transfected with either control or Smurf2 siRNA. Forty-eight hours post-transfection, cells were plated for clono-
genic survival assays as described in the Materials and Methods section. Survival fraction (SF) on Smurf2 knockdown was calculated
relative to the control siRNA-treated group (set at 1) and presented as mean ± SEM from three independent experiments. (B) Isogenic
colorectal cancer cell lines HCT-116 harboring either wild-type or mutant KRAS were transfected with either control or SM2 siRNA, and
clonogenic survival fraction was calculated as described above. (C) H358, H441, and H2347 cells were transduced with either two dif-
ferent Smurf2 shRNA (S3 and S4) or a scrambled (control) shRNA as detailed in the Materials and Methods section. Forty-eight hours
post-infection, cells were plated for clonogenic assays. Clonogenic survival of SMURF2 shRNA (S3 and S4) infected cells were calcu-
lated relative to the control shRNA-treated group (set at 1). Results are presented as mean ± SEM from three independent experiments.
H358 (3 × 105; as in D) and HCT116 (either wild-type or KRASG13D; as in E) cells were infected with either control or SM2-shRNA and
24 hours post-infection injected into the specified number of nude mice, and tumor appearance was observed by palpation on a regular
basis. Kaplan-Meier curves indicate the tumor-free survival in days. (F) Statistical analyses of the data obtained from tumor detection
studies are shown in tabulated fashion showing the median time-to-tumor detection. The table also shows the P values from a log-rank
test for any difference in the time-to-tumor development between two groups.
122 SMURF2:UBCH5 Maintains KRAS Protein Stability Shukla et al. Neoplasia Vol. 16, No. 2, 2014
of UBCH5 (Figure 3G , lower panel). Experiments using either wild-
type SMURF2 or ligase-dead SMURF2 (CA) demonstrated that
SMURF2 ubiquitin ligase activity is essential for UBCH5 monoubi-
quitination (Figure 6A). Under similar reaction conditions, SMURF2
did not ubiquitinate the other E2 enzyme, UBCH7 (Figure 6B).
MS/MS data further identified lysine (K) 144 as the site of monoubi-
quitination (Figure 6C ). From these studies, we hypothesized that
SMURF2 ligase activity may be essential in mediating UBCH5 mono-
ubiquitination, which may be critical in polyubiquitinating β-TrCP1.
To address the importance of SMURF2-mediated UBCH5 mono-
ubiquitination to KRAS stability, we tested the effects of wild-type
UBCH5 and K144R mutants on KRAS steady-state levels. As
shown in Figure 6D, lane 3, overexpression of wild-type UBCH5
caused a slight increase in KRAS steady-state level, whereas over-
expression of UBCH5 (K144R) mutant significantly reduced the
KRAS expression (Figure 6D, lane 5). Similar studies using catalyt-
ically inactive UBCH5 (C85A) mutant also caused KRAS destabili-
zation (Figure 6D, lane 4). Taken together, our data indicate that
SMURF2-mediated monoubiquitination of UBCH5 may be impor-
tant for β-TrCP1 polyubiquitination and critical for maintaining
KRAS levels and the loss of monoubiquitination or catalytic activity
of UBCH5 leads to KRAS degradation.
To understand the functionality of SMURF2-mediated monoubi-
quitination of UBCH5, we performed analytical SEC. As shown in
Figure 7, A and B, we detected SMURF2 and UBCH5 in the same
complex but only when we performed the in vitro ubiquitination
reaction before SEC analysis. From these observations, we hypothe-
sized that SMURF2-mediatedmonoubiquitination ofUBCH5promotes
the formation of a stable E3:E2 complex. Similarly, using HEK293
cells overexpressing SMURF2 and UBCH5 (Figure 7C ) and also
GST pull-down assays (Figure 7D), we confirmed SMURF2:UBCH5
interaction in the same immunocomplex as well as a direct interaction
between them. On the basis of these findings, we conclude that
SMURF2 mediates monoubiquitination of UBCH5 leading to auto-
activation through an effective E3:E2 complex formation.
Disruption of SMURF2:UBCH5 Interaction Reduces
KRAS Steady-State Levels
SEC, immunoprecipitation analysis, and GST pull-down assays
(Figure 7) identified a direct interaction between SMURF2 and
UBCH5. Although the exact contact point(s) between SMURF2
and UBCH5 is currently unknown, the crystal structure data available
between SMURF2 and UBCH7 revealed that 61PF62 and 95PA96 are
the critical residues in UBCH7 that mediate the E3:E2 interaction
[35]. Although, on the basis of primary amino acid alignment analysis,
UBCH7 show only 32% sequence identity with UBCH5, the proline,
phenylalanine (PF) and proline, alanine (PA) residues are conserved
between the two ubiquitin-conjugating enzymes (Figure W7). To
determine the importance of proline residues in UBCH5 on the main-
tenance of KRAS protein stability, we overexpressed the P61A and
P95A mutants in the context of KRAS. As shown in Figure 6D, lanes
6 and 7, overexpression of UBCH5 (P61A and P95A) mutants reduced
the KRAS steady-state levels similar to those produced by the UBCH5
(C85A) and UBCH5 (K144R) mutants. Taken together, our data
show that any alteration of either catalytic activity or disruption of
complex formation of SMURF2 and UBCH5 may be an effective
strategy to degrade mutant KRAS.
Discussion
Oncogenic KRAS remains an undruggable target in spite of decades
of effort attempting to target it either directly through controlling its
physical presence or its catalytic activity or indirectly by targeting its
downstream signaling particularly the RAF-MEK-ERK or phospho-
inositide 3-kinase (PI3K)-AKT pathway [44–47]. The recent identifi-
cation of ubiquitination-mediated regulation of KRAS protein stability,
Figure 5. Smurf2 and KRAS gene and protein expression are highly correlated among lung adenocarcinoma patients and cell lines. (A)
Scatter plot of KRAS and SMURF2 protein expression among different lung cancer, non–lung cancer, and noncancerous cell lines show-
ing positive correlation (r = 0.39, n = 25, P = .05). Cell lysates isolated from 25 different cell lines of lung cancer (H2347, Hcc78, H1793,
H838, H441, H2009, SK-Lu1, H460, A549, and H1975), non–lung cancer (U2OS, HeLa, UMSCC-1, UMSCC-11B, UMSCC-74B, Panc1,
SW620, and Lovo), and noncancerous cells (Het-1A, IMR-90, MH-S, MRC5, CHO, HDMEC, and skin fibroblasts) were subjected to immuno-
blot analysis using KRAS, SMURF2, and GAPDH antibodies. Band intensities (arbitrary units) were calculated as described in Figure 1B and
normalized using GAPDH. Log-transformed values of SMURF2/GAPDH and KRAS/GAPDHwere plotted and Pearson’s correlation coefficient
(r=0.39, n=25, P= .05) was calculated. (B) KRAS and Smurf2matched expression obtained from a large cohort of gene expressionmicro-
array data show a strong correlation among lung adenocarcinoma patients (r= 0.49, n= 594, P< .001) and lung cancer cell lines (r= 0.57,
n = 79, P < .005). However, the correlation was not as strong (r = 0.24, n = 130, P < .01) among patients with squamous lung cancer.
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GTP loading, and association with downstream partners [26,28,29] has
provided novel clues for developing efficient strategies to molecularly
target mutant KRAS-driven tumors. However, a clear understanding
of such ubiquitination-mediated regulation of KRAS still remained
largely unclear. In this report, we have identified SMURF2:UBCH5 as
a candidate E3:E2 complex that regulates the stability of KRAS; inter-
estingly, Smurf2 knockdown effects were more profound on mutant
KRAS as oppose to wild-type protein. Our data suggest that SMURF2
monoubiquitinates its cognate ubiquitin-conjugating enzyme (E2),
UBCH5/UBE2D, leading to the active E3:E2 complex formation.
Further, we show that this active SMURF2:UBCH5 complex is respon-
sible for polyubiquitinating and degrading another F-box family E3
ligase, β-TrCP1, which is known to degrade RAS including KRAS. In
addition, the loss of SMURF2 causes KRAS degradation leading to
pronounced reductions in clonogenic survival and tumor-forming
abilities of various cancer cells including mutant KRAS-driven ones.
The strong correlation between SMURF2 and KRAS protein and
transcript expression in human lung adenocarcinoma patients and
cell lines further strengthens the clinical and physiological relevance
of our observation. On the basis of these findings, in Figure 8, we
Figure 6. SMURF2 monoubiquitinates UBCH5 at K144 position. (A) GST-SM2 (either wild type or CA mutant) was purified using GST-
Sepharose beads, and in vitro ubiquitination reaction was performed and immunoblotted using indicated antibodies. (B) In vitro ubiqui-
tination assays were performed as above using wild-type SMURF2 in the presence and absence of either UBCH5 or UBCH7 as E2.
Immunoblot analyses were performed using indicated antibodies. (C) MS/MS spectrum of a peptide identifying ubiquitination of
K144 in UBCH5. Peptides isolated on in-gel digestion were resolved on a reverse phase column, and collision-induced dissociation
spectra were obtained using an Orbitrap XL mass spectrometer. An MS/MS corresponding to 140EWTQK*YAMox
147 of UBCH5 (pre-
cursor peptide m/z = 593.76) is shown above. Observed b- and y-ions are indicated. Modified Lys (K) is denoted with *. Mox = oxidized
methionine. (D) HEK293 cells were transfected with KRAS along with either wild type or mutants (C85A, K144R, P61A, and P95A) of
Myc-tagged UBCH5. Twelve hours post-transfection, cell lysates were prepared and subjected to immunoblot analysis.
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have proposed a model explaining the critical role of SMURF2:
UBCH5 in KRAS protein stability.
An important finding of this work was the differential effects of
SMURF2 loss on protein stability of wild-type versus mutant KRAS.
We found that physical loss, or loss of SMURF2 catalytic activity,
affected mutant KRAS protein’s steady-state level and half-life to a
greater degree than the wild-type protein. In many instances, protein
activity tends to correlate inversely with protein stability. For exam-
ple, the activated form of SRC kinase is less stable than its wild-type
or a kinase-dead counterpart [48], and a constitutively active mutant
RHEB GTPase has been reported to be unstable [49]. In case of
mutant KRAS, as it is known to be highly active compared to the
wild-type protein, we hypothesized and demonstrated here that
mutant KRAS protein is particularly labile specifically in the absence
of SMURF2 ligase activity and such observation is providing ratio-
nale to target SMURF2 to specifically kill mutant KRAS-dependent
cells. We would like to point out that although Smurf2 targeting is
found to be most effective against mutant KRAS-driven cells, it has
substantial effects on the clonogenic survival of wild-type KRAS-
driven cells as well. We believe that such effects are at least partially
attributable to Smurf2 targeting effects on EGFR [22].
Here, we also establish a direct inhibitory role of a HECT-type
ubiquitin ligase SMURF2 on a RING-type E3, β-TrCP1 protein
stability. Previously, we and others have reported that SMURF2 is
a unique E3 ligase, which can cause stabilization of its substrates
including mitotic arrest deficient 2 (MAD2) [50], human enhancer
of filamentation 1 (HEF1) [51], EGFR [22], mothers against decapen-
taplegic homolog 3 (SMAD3) [52], and mouse double minute 2 homo-
log (MDM2) [53] in a catalytic activity-dependent or -independent
manner. In the case of MDM2, SMURF2 promotes MDM2 stabi-
lization by enhancing its heterodimerization with MDMX [53]. In
contrast, β-TrCP1 degrades MDM2 and downregulates its activity
[54], thus counteracting SMURF2’s protective function. Similarly,
β-TrCP1 polyubiquitinates and degrades RAS family members
Figure 7. Monoubiquitinated UBCH5 forms a stable complex with SMURF2. (A and B) Purified GST-SMURF2 and recombinant UBCH5
(in A) and purified GST-SMURF2, UBCH5, and the ubiquitination machinery including E1, ubiquitin, and ATP (in B) were mixed, incubated,
and subjected to analytical SEC. The top panel is a representative spectrum. In the bottom panel, indicated fractions were subjected to
immunoblot analysis using indicated antibodies. The presence of both SM2 and UBCH5 in the same fraction indicates the formation of a
stable complex. (C) HEK293 cells were transfected with Myc-tagged UBCH5 in the presence or absence of FLAG-tagged SM2 wild type.
Twenty-four hours post-transfection, cells were treated with 3-MA in the indicated samples, and 4 hours post-treatment, lysates were
prepared. Cell lysates were then subjected to immunoprecipitation using Myc-agarose beads and immunoblotted with the indicated anti-
bodies. (D) Purified GST-SM2 (either wild type or CA) and purified UBCH5 was subjected to GST pull-down assay as described in the
Materials and Methods section. Immunoblot analysis was performed using indicated antibodies.
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including KRAS, whereas our data suggest that SMURF2 is respon-
sible for downregulating β-TrCP1 steady-state levels, thus indirectly
protecting KRAS from β-TrCP1–mediated degradation and pro-
moting oncogenesis. Furthermore, we show that SMURF2 is poly-
ubiquitinating and degrading β-TrCP1, suggesting the critical balance
of ubiquitin ligase activity in themaintenance of KRAS protein stability.
Similarly, whether β-TrCP1 has any counteractive effects on SMURF2
activity remains an open question. Furthermore, inverse correlations
between β-TrCP1 gene expression with either Smurf2 or KRAS expres-
sion in patients with lung adenocarcinoma also suggest the existence
of certain transcriptional/post-transcriptional regulation in the process,
an area of research that is beyond the scope of this work.
In this study, although we could recapitulate a previous report of
β-TrCP1 involvement in KRAS degradation [28], however, the mode
of degradation remains controversial. In 2009, Lu et al. reported that
the KRAS is the only RAS isoform, which undergoes lysosomal degra-
dation [36]. In contrast, Jeong et al. reported that β-TrCP–induced
RAS degradation is a proteasomal event [28]. In this study, we have
obtained data that a lysosomal inhibitor, 3-MA, can protect KRAS
from SMURF2 (CA)–induced degradation, whereas a proteasomal
inhibitor, MG132, was largely ineffective. Recently, in another study,
4-hydroxy-tamoxifen was reported to induce lysosome-mediated KRAS
degradation [55]. In the light of such controversy, we hypothesize that
such differences in the mode of KRAS degradation may be attributed to
different inducers of KRAS degradation and a more detailed analysis
may be necessary to resolve the issue.
While the present data suggest that SMURF2 could be an attrac-
tive molecular target to develop anti-KRAS therapy, our previous
observations of the role of SMURF2 as a major mitotic regulator
in spindle assembly checkpoint [50] and that forced alterations cause
chromosomal instability and aneuploidy and promote enhanced tumor
initiation in Smurf2-null mice [56] suggest that the inhibition of
SMURF2 catalytic activity or siRNA/shRNA-mediated targeting of
Smurf2 may not be an ideal strategy. However, our study also identified
a novel regulation of an E2 through an E3-mediated monoubiquiti-
nation that may provide a locus for a different strategy. Currently, there
are no reports of covalent ubiquitination of an E2 by its partner E3.We
identified SMURF2-mediated monoubiquitination of UBCH5 at the
lysine (K) 144 position, which may be responsible for its efficient
association to form the active E3:E2 complex required to downregulate
β-TrCP1. Furthermore, we also identified two proline residues located
at 61 and 95 positions in UBCH5, which may be critical for its associ-
ation with SMURF2 to form an active complex. Interestingly, although
the above-mentioned proline residues are conserved between UBCH5
and UBCH7, the surrounding 95PA96 amino acids are less conserved
between the two, andwe hypothesize that such differencesmight permit
specific targeting of the SMURF2:UBCH5 interaction without affect-
ing SMURF2:UBCH7 complex required for other cellular functions of
SMURF2. Thus, it seems possible that disruption of specific SMURF2:
UBCH5 interaction through either a peptidomimetic approach or by
small molecule inhibitors may offer a strategy for inducing mutant
KRAS degradation.
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Figure W1. SMURF2 controls mutant KRAS steady-state level. (A) Human cervical carcinoma, HeLa and human lung adenocarcinoma,
and A549 cells were treated with two different siRNA targeting different regions of Smurf2 (S1 and S2). Forty-eight hours post-
transfection, cell lysates were prepared and subjected to immunoblot analysis using indicated antibodies. We have also used two dif-
ferent KRAS antibodies as indicated in the Materials and Methods section. (B) H441 cells were transfected with either control (C),
Smurf2 (Sm2), AIP4 (A), or Smurf1 (Sm1) siRNA. Forty-eight hours post-transfection, cell lysates were subjected to immunoblot analysis
using indicated antibodies.
Figure W2. Smurf2 knockdown does not alter Kras transcript level.
Kras mRNA levels were quantitated using quantitative reverse
transcription–PCR as described in the Materials and Methods sec-
tion for the indicated cell lines 48 hours post siRNA transfection.
Figure W3. β-TrCP1 degrades KRAS. (A) H358 and H441 cells were transfected with either control (C) or β-TrCP1 (βT1) siRNA, and 48 hours
post-transfection, cell lysates were immunoblotted with the indicated antibodies. (B) HEK293 cells were co-transfected with either KRAS
alone or along with β-TrCP1 as indicated. Twenty-four hours post-transfection, whole-cell lysates were immunoblotted with the indicated
antibodies. (C) HEK293 cells were transfected with either KRAS alone or in combination with β-TrCP1 and where indicated treated with
the lysosomal inhibitor 3-MA as described in Figure 2. Cell lysates were subjected to immunoprecipitation with anti-KRAS antibody and
immunoblotted with the indicated antibodies.
Table W1. List of Smurf2 shRNA.
Smurf2 shRNA Sequences
shRNA#1 cagttaatccggaacattt
shRNA#2 gcccgagactctttaccat
shRNA#3 gtcacaacgacatagaaat
shRNA#4 ctgtgtttcatggacattata
shRNA#5 ctgacagtactctgtgcaa
shRNA#6 agcgagacctggttcagaa
shRNA#7 tggaagaatccagtatcta
shRNA#8 tggaagcgattaatgataa
Figure W4. Lentivirus shRNA-mediated knockdown of Smurf2 reduces KRAS steady-state levels. (A) Human isogenic colorectal cell line
HCT-116 harboring either wild-type or G13D Kras allele were transduced with either control or Smurf2 (S3) shRNA. Forty-eight hours
post transduction, cell lysates were prepared and subjected to immunoblot analysis using indicated antibodies. (B) Human lung adeno-
carcinoma cell lines, H358 and H441, were transduced with two different Smurf2 shRNA (S3 and S4), and immunoblot analysis was
performed using indicated antibodies.
Figure W5. Smurf2 mRNA expression is relatively higher in patients
with mutant Kras-containing lung adenocarcinoma. Smurf2 mRNA
expression levels were plotted with respect to Kras mutation status
(n = 26, wild-type Kras; n = 28, mutant Kras) confirmed among our
patients with lung adenocarcinoma.
Figure W6. β-TrCP1 gene expression is inversely correlated to both Smurf2 and Kras mRNA expression in patients with lung adeno-
carcinoma. (A) Smurf2 and β-TrCP1 (Btrc) gene expression obtained from a large cohort of gene expression microarray data showing
inverse correlation among lung adenocarcinoma patients (r = −0.41, n = 594, P < .0001), squamous cell cancer (r = −0.31, n = 130,
P= .0003), and lung cancer cell lines (r=−0.27, n= 79, P= .02). (B) Similar analysis between Kras and β-TrCP1 (Btrc) gene expression
also shows inverse correlation among lung adenocarcinoma patients (r=−0.52, n= 594, P< .0001), squamous cell cancer (r=−0.16,
n = 130, P = .07), and lung cancer cell lines (r = −0.25, n = 79, P = .03).
Figure W7. Partial sequence alignment between human ubiquitin-conjugating enzyme UBCH5 and UBCH7 showing 61PF62 and 95PA96
areas; * indicates amino acid identity in the area represented.
